Join our daily newsletter At The Bell to receive exclusive market insights
It’s been a bounce-back day for Australian shares, with yesterday’s bloodbath somewhat pared by +1.5% gains across the day on Trump’s “peace” boasts. It’s not been a slam-dunk green day for every stock, though, with some – including our top-trending company for today – instead still diving.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
With more than seven million users on the HotCopper forums, every discussion and speculation can move markets – which is why getting in front of those trends is so important for any trader worth their salt. In this daily HotCopper Trends column, we break down the top three Aussie stocks through each and every trading day, and why they’ve drawn a daily focus intraday.
American Tungsten and Antimony (ASX:AT4) was the most discussed stock on HotCopper by some distance Tuesday, after it dumped -17%.
Many users were disgruntled, considering it’s been such a strong rebound day in Oz, and especially because today’s drilling report seemed quite good. But some were rattled by the company admitting there’s “insufficient exploration to estimate a mineral resource,” while others were simply “underwhelmed.”
AT4 shares are currently selling at 13c/each.
(I’d also add American T&A is a client with The Market Link right now.)
Elsewhere, Telix Pharma (ASX:TLX) reported positive early outcomes from its ongoing Phase Three ProstACT study (currently in its first steps). The company has been working on prostate cancer treatments.
This was more welcomed than the top-billed release, and TLX popped +7%. It’s now selling above $10/sh and is up around +12% month on month.
And finally, Imugene (ASX:IMU) found its way into top discussions like its often want to do on HotCopper. (Who doesn’t love seeing the 33K-reply thread “Why IMU is a multi multi bagger” as a morning ritual?)
Now, those bags are just having to wait, though, because Imugene paused this morning to share its latest azer-cel study results.
Early info seems good, and indicative pricing suggests IMU will open +4.35% higher once traders get a chance to bite. The data: Imugene has seen “strong response rates” in certain lymphoma and leukemia subtypes when applying its Azer Cel treatment in Phase 1B studies, the company explained today.
While IMU has struggled somewhat in CY26 and is down -37% YTD, this may be the action it needs to climb back above its 23cps.
And looking wider, the ASX has been up +1.34%.
That’s Tuesday’s HotCopper Market Trends, I’m Isaac McIntyre – see you for close.
Join the discussion. See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
